Key result
Pantoprazole clearance in ACS is associated with CRP levels and concurrent statin use.
Why the study?
Pantoprazole pharmacokinetic properties are not fully characterized in patients with acute coronary syndrome on dual antiplatelet therapy.
What factors influence the variability in pantoprazole pharmacokinetics in patients with acute coronary syndrome on dual antiplatelet therapy?
Population
93 adult males and females with acute coronary syndrome on dual antiplatelet therapy
Comparison
None; analysis of pantoprazole pharmacokinetics with covariates
Design
Nonlinear mixed-effects modeling observational study
Authors
Loading...
May alter pantoprazole exposure in ACS; hypothesis-generating for individualized dosing, requires prospective validation.
Observational (n=93)
No
What factors influence the variability in pantoprazole pharmacokinetics in patients with acute coronary syndrome on dual antiplatelet therapy?
p-value: p=<0.01
Pantoprazole clearance in ACS patients on DAPT is influenced by CRP levels and statin use, suggesting a need for individualized dosing.
Nikolić et al. (2023) conducted an observational in Acute coronary syndrome (n=93). Pantoprazole was evaluated on Pantoprazole clearance (p=<0.01). Pantoprazole clearance in patients with acute coronary syndrome is significantly influenced by C-reactive protein levels and concurrent use of statins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: